HRID1945711

反应详情

EQUATION

反应方程式

REACTANTS

反应物

HCID311870

4-bromoisoquinolin-1-amine

C9H7BrN2

结构：CCC[CH2][Sn]([CH2]CCC)([CH2]CCC)[c]1nc(N2CCOCC2)c2nc(CN3CCC(C(C)(C)C)CC3)n(C)c2n1

HCID59605631

未命名化合物

PRODUCTS

生成物

结构：Cn1c(CN2CCC(C(C)(C)C)CC2)nc2c(N3CCOCC3)nc(-c3cnc(N)c4ccccc34)nc21

HCID59605564

未命名化合物

PROCEDURE

实验过程

4-(8-((4-tert-butylpiperidin-1-yl)methyl)-9-methyl-2-(tributylstannyl)-9H-purin-6-yl)morpholine (0.1 g) was reacted with 4-bromoisoquinolin-1-amine via General Procedure D to afford 114 (10 mg) following reverse phase purification. MS (Q1) 515.3 (M)+. 1H NMR (500 MHz, CDCl3) δ 9.02 (d, 1H), 7.94-7.45 (m, 6H), 4.35 (s, 4H), 4.02-3.61 (m, 9H), 2.97 (s, 2H), 2.13 (s, 2H), 1.92-1.52 (m, 5H), 1.52-0.68 (m, 26H)

来源与证据

来源类型: Open Reaction Database
ORD 记录: ord-92ff9415416d484fa896e05624f962d7
来源数据集: uspto-grants-2013_03
DOI: 10.6084/m9.figshare.5104873.v1
专利: US08394796B2
来源说明: uspto-grants-2013_03

反应 SMILES

[C:1]([CH:5]1[CH2:10][CH2:9][N:8]([CH2:11][C:12]2[N:13]([CH3:40])[C:14]3[C:19]([N:20]=2)=[C:18]([N:21]2[CH2:26][CH2:25][O:24][CH2:23][CH2:22]2)[N:17]=[C:16]([Sn](CCCC)(CCCC)CCCC)[N:15]=3)[CH2:7][CH2:6]1)([CH3:4])([CH3:3])[CH3:2].Br[C:42]1[C:51]2[C:46](=[CH:47][CH:48]=[CH:49][CH:50]=2)[C:45]([NH2:52])=[N:44][CH:43]=1>>[C:1]([CH:5]1[CH2:6][CH2:7][N:8]([CH2:11][C:12]2[N:13]([CH3:40])[C:14]3[C:19]([N:20]=2)=[C:18]([N:21]2[CH2:26][CH2:25][O:24][CH2:23][CH2:22]2)[N:17]=[C:16]([C:42]2[C:51]4[C:46](=[CH:47][CH:48]=[CH:49][CH:50]=4)[C:45]([NH2:52])=[N:44][CH:43]=2)[N:15]=3)[CH2:9][CH2:10]1)([CH3:4])([CH3:2])[CH3:3]